EPISODE · Dec 5, 2018 · 59 MIN
Future Value Generation in Immuno-Oncology
from PharmaTalkRadio · host Conference Forum
In this podcast, originally recorded at the 4th annual annual Immuno-Oncology 360° 2018 event, Dr Axel Hoos, SVP, Oncology R&D, GSK, led a panel on The Future Value Generation in IO. Dr Hoos was joined by expert analyst Dr Andrew Baum, Head of Global Healthcare and Managing Director of Equity Research for Citi along with Dr David Grayzel, Partner of Atlas Venture, Dr Simeon George, Partner of SR One and Mark Simon, Partner of Torreya Partners. Key discussion points included: What is the most important IO event or trend that will carry us forward and shape the IO space?With the ever expanding range of indications, what is next and how do we get there?What have we learned from precision medicine and how can that be applied to IO?Which biomarker is next that will follow PDL1 and that will help guide the field in patient selection?With the many opportunities now with modalities, what do you think is a valuable next modality that could be important?With the maturing and evolving IO landscape, has that changed investment sentiment? For the latest news in immunotherapy, join us at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY.
What this episode covers
In this podcast, originally recorded at the 4th annual annual Immuno-Oncology 360° 2018 event, Dr Axel Hoos, SVP, Oncology R&D, GSK, led a panel on The Future Value Generation in IO. Dr Hoos was joined by expert analyst Dr Andrew Baum, Head of Global Healthcare and Managing Director of Equity Research for Citi along with Dr David Grayzel, Partner of Atlas Venture, Dr Simeon George, Partner of SR One and Mark Simon, Partner of Torreya Partners. Key discussion points included: What is the most important IO event or trend that will carry us forward and shape the IO space?With the ever expanding range of indications, what is next and how do we get there?What have we learned from precision medicine and how can that be applied to IO?Which biomarker is next that will follow PDL1 and that will help guide the field in patient selection?With the many opportunities now with modalities, what do you think is a valuable next modality that could be important?With the maturing and evolving IO landscape, has that changed investment sentiment? For the latest news in immunotherapy, join us at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY.
NOW PLAYING
Future Value Generation in Immuno-Oncology
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.